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Recent challenges to the humanity include new viral 
diseases that are caused, for example, by a previously 
unknown human metapneumovirus, novel types of 
coronaviruses, and the influenza viruses.1,2 Influenza and 
acute respiratory viral infections account for approximately 
90% of infectious respiratory pathologies in humans. The 
annual case load due to these diseases in the Russian 
Federation ranges from 18 to 33 million patients. Among 
them, influenza represents the greatest concern because of 
its rapid transmission, severe cource of disease, and the 
probability of occurrence of serious complications. Specific 
treatments of influenza rely on drugs belonging to several 
chemical categories, differing by their molecular targets 
and the mechanism of action. Prominent examples include 
the M2 ion channel inhibitors rimantadine and amantadine, 
the neuraminidase inhibitors oseltamivir, zanamivir, 
peramivir, and laninamivir,3 as well as the viral polymerase 
complex blocker baloxavir marboxil.4 Umifenovir 
(Arbidol) is a viral hemagglutinin blocker that has been 
approved for use in Russia, China, and several other 
countries.5 However, the properties of influenza virus 
genome enable rapid emergence of strains resistant to the 
action of known antiviral drugs, while the virus retains its 
virulence and pathogenicity.6 A series of nucleoside 
analogs are effective against influenza. For example, 
favipiravir is a broad spectrum antiviral drug developed in 
Japan.7 The well-known drug ribavirin, which also belongs 
to this group, shows anti-influenza properties as well. 
However, these drugs are not frequently prescribed against 
influenza due to their significant side effects. 
Pathogens belonging to the genus of enteroviruses, such 
as Coxsackie B viruses, are also the source of major human 
health concerns. These non-enveloped viruses containing 
positive-sense RNA genome are the causative agents for a 
broad spectrum of pathologies, including pericarditis and 
myocarditis, poliomyelitis, nonspecific febrile illness, serous 
meningitis, meningoencephalitis, and other diseases. 
Myocarditis associated with Coxsackie virus infection is 
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exceedingly difficult for diagnosis and treatment, due to 
both clinical issues (a variable degree of organic and 
functional damage to the myocardium, difficulty in 
obtaining biopsy samples, and the absence of clear disease 
markers), as well as taking into account the absence of 
effective agents for etiotropic treatment.8 Taking into 
account all of the aforementioned factors, it should be 
recognized that the development of new, effective antiviral 
agents, including drugs against Coxsackie B3 virus, is a 
high priority task for medicinal chemistry and practical 
healthcare. 
Azolo[5,1-с][1,2,4]triazines are heterocyclic systems 
that possess a range of useful biological properties.9 The 
steady interest of researchers toward such compounds is 
primarily motivated by their structural similarity to the 
heterocyclic nucleobases of DNA and RNA. Such structu-
ral characteristics are associated with antimetabolite 
activity, which can be instrumental for designing effective 
biologically active compounds. A particular interest in this 
area has been attracted by compounds bearing a nitro group 
in the [1,2,4]triazine ring, which have shown a broad range 
of antiviral activity. This class of compounds is represented 
by Triazavirin (6-methylsulfanyl-3-nitro[1,2,4]triazolo[5,1-c]-
[1,2,4]triazin-4-one sodium salt dihydrate), which has been 
approved for human use in the treatment of influenza, acute 
respiratory viral infections, and tick-borne encephalitis.10–15 
The syntheses of azolo[1,2,4]triazine ring systems have 
been accomplished according to two main approaches: the 
annulation of an azole ring to an existing [1,2,4]triazine 
ring or the assembly of a triazine moiety on the basis of 
azole-containing starting material.16 Nitro synthons have 
been of particular interest in the synthesis of azolo[1,2,4]tri-
azines. Suitable nitro components that have been used in 
these syntheses are ethyl nitroacetate,9 ethyl nitro-
malonate,17 nitroacetonitrile,18–20 nitromalonic aldehyde,17 
and nitroacetaldehyde in the form of its potassium salt.21 
Promising synthetic building blocks for the assembly of 
triazine ring include α-nitro ketones, which are highly 
reactive compounds with a broad synthetic potential but 
low thermodynamic stability, which is a drawback for their 
synthetic applications. In our earlier study we have 
described a new, effective method for the synthesis of α-nitro 
ketone salts 5a,b from nitroenamines 4a,b that, in turn, 
were obtained from nitromethane (1), ortho esters 2a,b, and 
morpholine (3) (Scheme 1).22,23 
Only isolated examples of alkyl-1,4-dihydroazolo[1,2,4]-
triazin-4-ols have been described in the literature. Similar 
compounds have been obtained using 3-fluoroalkyl-3-oxo-
propanoate and its analogs,24,25 which are costly compounds 
with limited availability. The described 4-fluoroalkyl-1,4-di-
hydroazolo[5,1-с][1,2,4]triazin-4-ols were characterized 
with respect to their inhibitory activity against mixed type 
carboxylesterase.24 
The structures of 4-alkylazolo[5,1-с][1,2,4]triazin-4-ols 
8a–l were characterized by IR, 1Н and 13С NMR 
spectroscopy, as well as by elemental analysis. A crystal of 
compound 8j (Fig. 1) was subjected to X-ray structural 
analysis (Fig. 1). 1Н NMR spectra of 4-alkylazolo[5,1-с]-
[1,2,4]triazin-4-ols 8a–l contained characteristic upfield 
signals of alkyl group at position 4 of the triazine ring, as 
well as a hydroxy group singlet in the region of 5.97– 
7.92 ppm. 13С NMR spectra of compounds 8a–l also 
contained characteristic upfield signals of alkyl group at the 
triazine ring position 4, as well as signals assigned to the 
azole ring substituents. Characteristic IR absorption bands 
in the regions of 1530–1580 and 1316–1338 cm–1 belonged 
to the nitro group. 
Scheme 2 
Figure 1. The molecular structure of compound 8j with atoms 
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Azo coupling of 1-nitro-2-propanone sodium salt (5a) or 
1-nitro-2-butanone sodium salt (5b) with 5-diazoazoles 7a–f 
obtained in situ from amines 6a–f led to the formation of 
new 4-methyl-3-nitro-1,4-dihydroazolo[5,1-с][1,2,4]triazin- 
4-ols 8a–f and 4-ethyl-3-nitro-1,4-dihydroazolo[5,1-с]-
[1,2,4]triazin-4-ols 8g–l in 25–53% yields (Scheme 2).  
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In the case of compound 8j, it was shown that 
compounds belonging to the 4-alkyl-3-nitro-1,4-dihydroazolo-
[5,1-с][1,2,4]triazin-4-ol series can undergo the elimination 
of H2O molecule upon gradual heating, forming the 
conjugated triazolotriazine system 9 (Scheme 3). The 
structure of compound 9 was confirmed by 1Н NMR 
spectroscopy data. Its characteristic 1H NMR features 
included a doublet at 2.27 ppm, which was assigned to the 
methyl group, and a quartet signal of the methylene moiety 
at 5.76 ppm. Compound 9 was also characterized by IR 
spectroscopy, 13С NMR spectroscopy, and elemental 
analysis.  
highest concentrations tested (300 µg/ml, 1415 µM). Despite 
the small number of compounds that were tested, a trend of 
increased toxicity in compounds of this group can be 
associated with the presence of methylsulfanyl or trifluoro-
methyl substituent in the azole ring. 
Among all of the obtained representatives, only 
compound 8i containing a methylsulfanyl substituent showed 
a moderate antiviral activity against the influenza virus. 
The other compounds suppressed the viral reproduction to 
a certain degree only at nearly toxic concentrations. It 
should be noted that the known antiviral drug Triazavirin, 
belonging to the class of azoloazines, also contains a 
methylsulfanyl moiety. Apparently, this structural motif 
should be viewed as an important promoter of anti-
influenza activity in the case of azoloazines, providing 
guidance for further optimization and focusing of chemical 
libraries. Regarding the phylogenetically distant Coxsackie 
B3 virus, none of the analyzed candidates, including 
compound 8i, showed inhibiting activity. The IC50 values 
in this case were on the range of hundreds of µM and were 
close to the toxicity limit for these compounds. This 
observation should be interpreted as evidence of a specific 
mechanism of action for compound 8i against the influenza 
virus, explained by the presence of a particular 
functionality. 
Thus, we have synthesized a series of 4-alkyl-3-nitro-
1,4-dihydroazolo[5,1-с][1,2,4]triazines by using α-nitro 
ketone salts. The obtained compounds were characterized 
with respect to their cytotoxic properties in cell culture, as 
well as their inhibitory activity against phylogenetically 
unrelated viruses – the influenza virus and Coxsackie B3 
virus. The obtained results and literature data indicate that 
azolo[5,1-с][1,2,4]triazines are promising objects for 
further medicinal chemistry research. 
Experimental 
IR spectra were recorded on a Bruker Alpha 
spectrometer equipped with a ZnSe ATR accessory. 1Н, 
13C, and 19F NMR spectra were recorded on a Bruker 
Avance NEO 600 instrument (600, 151, and 565 MHz, 
respectively) for samples in CD3CN and Me2CO-d6 
solutions, with TMS used as internal standard. Elemental 
analyses were performed on a PerkinElmer 2400 Series II  
CHNS elemental analyzer. Melting points were determined 
on an Electrothermal IA 9100 melting point apparatus. The 
reaction progress and purity of the obtained compounds 
were controlled by TLC using Silufol UV-254 plates. 
This study was performed using commercially available 
reagents and solvents without additional purification, 
unless indicated otherwise. 
Preparation of 3-nitro-1,4-dihydroazolo[5,1-c][1,2,4]-
triazin-4-ols 8a–l (General method). A solution of NaNO2 
(0.76 g, 0.011 mol) in H2O (2 ml) was added portionwise to 
a solution of 3-aminoazole 6a–f (0.01 mol) in H2O (4 ml) 
and concd HCl (6 ml, 0.072 mol) at –10÷–7°С. The 
reaction mixture was stirred for 10 min and treated by 
adding a solution of 1-nitropropan-2-one sodium salt 
monohydrate (5a) (0.01 mol) or 1-nitrobutan-2-one sodium 
salt (5b) (0.01 mol) in H2O (6 ml). The mixture was stirred 
Scheme 3 
Some of the synthesized series of compounds 8a–l were  
characterized with respect to their biological activity. Thus, 
their cytotoxic properties were determined in a cell culture, 
as well as their inhibitory activity was determined against 
two phylogenetically unrelated viruses – the influenza virus 
and Coxsackie B3 virus (Table 1). 
According to the obtained data, the studied compounds 
exhibited a broad range of toxicity. The most toxic was 
compound 8f (CC50 139 µM), while the least toxic was 
compound 8b, which did not cause cell death up to the 
Table 1. The cytotoxic and antiviral properties of 

















8a N/T*4 N/T – N/T N/T – 
8b >1415 472±30 3 N/T N/T – 
8с N/T N/T – N/T N/T – 
8d N/T N/T – N/T N/T – 
8e 371 ± 22 >370 1 N/T N/T – 
8f 139 ± 11 91 ± 12 2 N/T N/T – 
8g 742 ± 51 >469 2 390 >235 2 
8h 907 ± 78 233 ± 29 4 436 >220 2 
8i 419 ± 36 32 ± 4 13 368 >194 2 
8j 432 ± 28 >357 1 425 129 3 
8k >1056 >1056 1 N/T N/T – 
8l 1060 ± 55 336 ± 40 3 777 >353 2 
Ribavirin >2130 39 ± 5 55 >2130 56 ± 8 38 
* СС50 – 50% cytotoxic concentration – the concentration of test compound 
resulting in death of 50% of cells. 
** IC50 – 50% inhibitory concentration – the concentration of test 
compound reducing the virus titer by 50%, compared to the blank control. 
*** SI – selectivity index – the ratio of CC50 to IC50. 
*4 N/T (Not Tested) – not determined. 
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for 30 min at –10÷–7°С and then for 1 h at room 
temperature. The product was extracted with EtOAc, the 
solvent was evaporated, the residue was stirred with CHCl3 
(20 ml) for 30 min and filtered off, then washed with EtOH. 
4-Methyl-3-nitro-1,4-dihydro[1,2,4]triazolo[5,1-с][1,2,4]-
triazin-4-ol (8a). Yield 0.71 g (36%), yellow powder, 
mp 146–148°С (EtOAc). IR spectrum, ν, cm–1: 3223 (О–Н), 
3141 (N–H), 1530, 1320 (NO2), 1206, 1184 (С–О). 
1H NMR spectrum (Me2CO-d6), δ, ppm: 2.40 (3Н, s, СН3); 
7.03 (1Н, s, СН); 7.86 (1Н, s, ОН); 12.12 (1Н, s, NH). 
13C NMR spectrum (Me2CO-d6), δ, ppm: 25.5; 83.2; 144.4; 
146.5; 152.1. Found, %: С 30.69; H 3.05; N 42.62. 
С5H6N6O3. Calculated, %: С 30.31; H 3.05; N 42.21. 
4,7-Dimethyl-3-nitro-1,4-dihydro[1,2,4]triazolo[5,1-с]-
[1,2,4]triazin-4-ol (8b). Yield 0.53 g (25%), yellow 
powder, mp 151–153°С (decomp.). IR spectrum, ν, cm–1: 
3264 (О–Н), 3100 (N–H), 1556, 1318 (NO2), 1174 (С–О). 
1H NMR spectrum (Me2CO-d6), δ, ppm: 2.26 (3Н, s, СН3); 
2.36 (3Н, s, СН3); 6.89 (1Н, s, ОН); 11.98 (1Н, s, NH). 
13C NMR spectrum (Me2CO-d6), δ, ppm: 14.5; 25.6; 82.9; 
144.5; 146.7; 161.4. Found, %: С 33.91; H 3.81; N 39.54. 
С6H8N6O3. Calculated, %: 33.97; H 3.80; N 39.61. 
4-Methyl-7-(methylsulfanyl)-3-nitro-1,4-dihydro[1,2,4]-
triazolo[5,1-с][1,2,4]triazin-4-ol (8c). Yield 0.63 g (26%), 
yellow powder, mp 151–153°С (EtOAc). IR spectrum, 
ν, cm–1: 3250 (О–Н), 3168 (N–H w), 1556, 1316 (NO2), 
1157 (С–О). 1H NMR spectrum (Me2CO-d6), δ, ppm: 2.37 
(3Н, s, СН3); 2.56 (3Н, s, SСН3); 6.99 (1Н, s, ОН); 12.07 
(1Н, s, NH). 13C NMR spectrum (Me2CO-d6), δ, ppm: 14.0; 
25.4; 83.1; 144.7; 147.2; 162.8. Found, %: С 29.51; 
H 3.18; N 34.05. С6H8N6O3S. Calculated, %: С 29.51; 
H 3.30; N 34.41.  
4-Methyl-3-nitro-7-(trifluoromethyl)-1,4-dihydro[1,2,4]-
triazolo[5,1-с][1,2,4]triazin-4-ol (8d). Yield 0.85 g (32%), 
yellow powder, mp 164–166°С (EtOAc). IR spectrum, 
ν, cm–1: 3329 (О–Н), 3196 (N–H), 1539, 1329 (NO2), 1152 
(С–F). 1H NMR spectrum (Me2CO-d6), δ, ppm: 2.43 (3Н, 
s, СН3); 7.37 (1Н, s, ОН); 12.41 (1Н, s, NH). 
13C NMR 
spectrum (Me2CO-d6), δ, ppm (J, Hz): 25.4; 84.2; 120.2 (q, 
J = 269.2); 144.8; 147.8; 153.5 (q, J = 39.6). 19F NMR 
spectrum (Me2CO-d6), δ, ppm: –66.65 (CF3). Found, %: 
С 27.14; H 1.66; N 31.55. С6H5N6O3F3. Calculated, %: 
С 27.08; H 1.89; N 31.58.  
Ethyl 4-hydroxy-4-methyl-3-nitro-1,4-dihydro[1,2,4]-
triazolo[5,1-с][1,2,4]triazine-7-carboxylate (8e). Yield 
1.11 g (41%), yellow powder, mp 194–196°С (EtOAc). 
IR spectrum, ν, cm–1: 3272 (О–Н), 1676 (С=О), 1579, 
1322 (NO2), 1148 (С–О). 
1H NMR spectrum (Me2CO-d6), 
δ, ppm (J, Hz): 1.37 (3Н, t, J = 7.1, СН3); 2.44 (3H, s, 
CH3); 4.35–4.44 (2Н, m, СН2); 7.22 (1Н, s, ОН); 12.28 
(1Н, s, NH). 13C NMR spectrum (Me2CO-d6), δ, ppm: 14.5; 
25.6; 62.3; 84.1; 144.6; 147.2; 154.8; 160.1. Found, %: 
С 35.40; H 3.90; N 31.32. С8H10N6O5. Calculated, %: 
C 35.56; H 3.73; N 31.10.  
Ethyl 4-hydroxy-4-methyl-3-nitro-1,4-dihydropyrazolo-
[5,1-с][1,2,4]triazine-8-carboxylate (8f). Yield 1.34 g 
(50%), yellow powder, mp 153–155°С (EtOAc). IR spect-
rum, ν, cm–1: 3272 (О–Н), 1676 (С=О), 1579, 1322 (NO2), 
1148 (С–О). 1H NMR spectrum (Me2CO-d6), δ, ppm 
(J, Hz): 1.32 (3Н, t, J = 7.1, СН3); 2.42 (3H, s, CH3); 4.32 
(2Н, q, J = 7.1, СН2); 6.96 (1H, s, CH); 7.90 (1Н, s, ОН); 
11.48 (1Н, s, NH). 13C NMR spectrum (Me2CO-d6), δ, ppm: 
14.9; 25.2; 60.9; 81.8; 97.4; 138.6; 142.1; 144.9; 162.7. 
Found, %: С 39.64; H 3.92; N 25.81. С9H11N5O5. 
Calculated, %: С 40.15; H 4.12; N 26.01.  
4-Ethyl-3-nitro-1,4-dihydro[1,2,4]triazolo[5,1-с][1,2,4]-
triazin-4-ol (8g). Yield 1.09 g (51%), yellow powder, 
mp 147–149°С (EtOAc). IR spectrum, ν, cm–1: 1540, 1321 
(NO2), 1029 (С–О). 
1H NMR spectrum (CD3CN), δ, ppm 
(J, Hz): 0.65 (3Н, t, J = 7.5, СН3); 2.68–2.80 (2Н, m, СН2); 
5.72 (1Н, s, СН); 7.84 (1Н, s, ОН); 10.82 (1Н, s, NH). 
13C NMR spectrum (СD3СN), δ, ppm: 8.7; 31.1; 87.9; 
143.4; 147.4; 152.5. Found, %: С 33.80; H 3.73; N 39.26. 
С6H8N6O3. Calculated, %: С 33.97; H 3.80; N 39.61.  
4-Ethyl-7-methyl-3-nitro-1,4-dihydro[1,2,4]triazolo-
[5,1-с][1,2,4]triazin-4-ol (8h). Yield 0.98 g (43%), yellow 
powder, mp 163–165°С (EtOAc). IR spectrum, ν, cm–1: 
1545, 1330 (NO2 s), 1132 (С–О s). 
1H NMR spectrum 
(Me2CO-d6), δ, ppm (J, Hz): 0.71 (3Н, t, J = 7.5, СН3); 
2.27 (3Н, s, СН3); 2.74–2.88 (2Н, m, СН2); 6.98 (1Н, s, 
ОН); 12.04 (1Н, s, NH). 13C NMR spectrum (Me2CO-d6), 
δ, ppm: 8.6; 14.4; 30.9; 87.3; 142.9; 147.2; 162.1. Found, 
%: С 37.06; H 4.54; N 37.22. С7H10N6O3. Calculated, %: 
С 37.17; H 4.46; N 37.15.  
4-Ethyl-7-(methylsulfanyl)-3-nitro-1,4-dihydro[1,2,4]-
triazolo[5,1-с][1,2,4]triazin-4-ol (8i). Yield 1.18 g (46%), 
yellow powder, mp 151–153°С (EtOAc). IR spectrum, 
ν, cm–1: 1539, 1326 (NO2 s), 1133 (С–О s). 
1H NMR 
spectrum (Me2CO-d6), δ, ppm (J, Hz): 0.75 (3Н, t, J = 7.5, 
СН3); 2.56 (3Н, s, SСН3); 2.73–2.89 (2Н, m, СН2); 7.05 
(1Н, s, ОН); 12.10 (1Н, s, NH). 13C NMR spectrum 
(Me2CO-d6), δ, ppm: 8.8; 14.1; 30.9; 87.9; 143.7; 148.1; 
163.3. Found, %: С 32.60; H 3.93; N 32.56. С7H10N6O3S. 
Calculated, %: С 32.55; H 3.90; N 32.54.  
4-Ethyl-3-nitro-7-(trifluoromethyl)-1,4-dihydro[1,2,4]-
triazolo[5,1-с][1,2,4]triazin-4-ol (8j). Yield 1.50 g (53%), 
yellow powder, mp 171–173°С (EtOAc). IR spectrum, 
ν, cm–1: 3431 (O–H), 1553, 1338 (NO2), 1157 (C–F), 1133 
(С–О). 1H NMR spectrum (СD3СN), δ, ppm (J, Hz): 0.70 
(3Н, t, J = 7.5, СН3); 2.68–2.78 (2Н, m, СН2); 5.97 (1Н, s, 
ОН); 10.97 (1Н, s, NH). 13C NMR spectrum (СD3СN), 
δ, ppm (J, Hz): 8.6; 31.3; 88.8; 120.1 (q, J = 270.3); 143.8; 
148.7; 153.9 (q, J = 39.3). 19F NMR spectrum (СD3СN), 
δ, ppm: –67.13 (CF3). Found, %: С 29.91; H 2.48; N 30.00. 
С7H7N6O3F3. Calculated, %: С 30.01; H  2.52; N 30.00.  
Ethyl 4-ethyl-4-hydroxy-3-nitro-1,4-dihydro[1,2,4]-
triazolo[5,1-с][1,2,4]triazine-7-carboxylate (8k). Yield 
1.13 g (40%), yellow powder, mp 189–191°С (EtOAc). 
IR spectrum, ν, cm–1: 1748 (С=О), 1540, 1328 (NO2), 1033 
(С–О). 1H NMR spectrum (Me2CO-d6), δ, ppm (J, Hz): 
0.75 (3Н, t, J =7.5, СН3); 1.37 (3Н, t, J = 7.1, СН3); 2.82–
2.92 (3H, m, CH3); 4.35–4.44 (2Н, m, СН2); 7.37 (1Н, s, 
ОН); 12.35 (1Н, s, NH). 13C NMR spectrum (Me2CO-d6), 
δ, ppm: 8.7; 14.5; 31.4; 62.4; 88.7; 143.5; 148.1; 155.2; 
160.0. Found, %: С 38.01; H 4.11; N 29.61. С9H12N6O5. 
Calculated, %: С 38.03; H 4.26; N 29.57.  
Ethyl 4-ethyl-4-hydroxy-3-nitro-1,4-dihydropyrazolo-
[5,1-с][1,2,4]triazine-8-carboxylate (8l). Yield 1.34 g (50%), 
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yellow powder, mp 184–186°С (EtOAc). IR spectrum, 
ν, cm–1: 3256 (О–Н), 3128 (N–H), 1682 (С=О), 1580, 
1317 (NO2), 1156, 1116 (С–О). 
1H NMR spectrum 
(Me2CO-d6), δ, ppm (J, Hz): 0.69 (3Н, t, J = 7.5, СН3); 
1.33 (3Н, t, J = 7.1, СН3); 2.78–3.02 (2Н, m, СН2); 4.29–
4.37 (2Н, m, СН2); 7.05 (1H, s, CH); 7.92 (1Н, s, ОН); 
11.52 (1Н, s, NH). 13C NMR spectrum (Me2CO-d6), 
δ, ppm: 8.8; 14.8; 30.7; 60.9; 86.5; 97.4; 139.4; 142.5; 
143.7; 162.6. Found, %: С 42.06; H 4.57; N 23.68. 




triazin-4-ol (8j) 0.28 g (0.001 mol) was heated at 120°С 
without solvent and maintained for 4 h. Yield 0.26 g (98%), 
brown powder, mp 174–176°С. IR spectrum, ν, cm–1: 1540, 
1362 (NO2), 1148 (C–F). 
1H NMR spectrum (Me2CO-d6), 
δ, ppm (J, Hz): 2.27 (3Н, d, J = 7.7, СН3); 5.76 (1Н, q, 
J = 7.7, СН); 12.17 (1Н, s, NH). 13C NMR spectrum 
(Me2CO-d6), δ, ppm (J, Hz): 12.9; 111.2; 119.9 (q, 
J = 269.3); 121.1; 147.6; 149.6; 153.4 (q, J = 39.4). 
19F NMR spectrum (C3D6O), δ, ppm: –66.88 (3F, CF3). 
Found, %: С 32.04; H 1.74; N 31.92. С7H5N6O2F3. 
Calculated, %: С 32.07; H 1.92; N 32.06. 
Cytotoxic activity study of compounds 8a–l in cell 
culture was performed on the basis of cell viability evaluation 
using the reduction reaction of tetrazolium dye МТТ 
(3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide) by cells in the culture, the intensity of which 
reflected the degree of cell viability as indicated by the 
reduction of dye by cellular dehydrogenases. 
The influenza virus strain A/Puerto Rico/8/34 (H1N1) 
was cultured in MDCK cells, while Coxsackie B3 virus was 
cultured in Vero cells. The compounds under investigation 
dissolved at the concentration range of 4–300 µg/ml (for 
the influenza virus) and 12.5–400 µg/ml (for the Coxsackie 
B3 virus) in the cell culture medium, were added into the 
wells of a 96-well plate with a monolayer of cells at the 
volume of 200 µl/well, followed by incubation for 48 h at 
37°С at 5% СО2. Cells were further washed with α-MEM 
medium and 100 µl of MTT solution (0.5 mg/ml) in cell 
culture medium was added to each well of the plate. The 
cells were incubated at 37°С at 5% СО2 for 2 h and washed 
for 5 min with saline. The precipitate was dissolved in 
DMSO (100 µl in each well of the plate), followed by 
optical density measurement using a Thermo Scientific 
Multiskan FC microplate reader at 540 nm wavelength. 
The 50% cytotoxic concentration (СС50) was calculated on 
the basis of the obtained data, reflecting the concentration 
of the compound that reduced the optical density in the 
wells by 50%, compared to intact cells. 
Antiviral activity testing of compounds 8a–l. The 
antiviral activity was determined against the A/Puerto 
Rico/8/34 (H1N1) strain of influenza virus and the 
Coxsackie B3 virus (strain Nancy). The solutions of  
compounds under investigation dissolved at the 
concentration range of 4–300 µg/ml (for the influenza 
virus) and 12.5–400 µg/ml (for the Coxsackie B3 virus) in 
the cell culture medium (100 µl) were added into the plate 
wells containing a monolayer of MDCK cells for influenza 
virus or Vero cells for Coxsackie B3 virus. The plates with 
cells were incubated at 5% CO2 at 37°С for 1 h. 
Subsequently, the respective virus (100 µl) was added to 
the wells (at m.o.i. 0.01), and the plates were incubated for 
48 h at 5% CO2 at 37°С. After the incubation period, the 
cells were washed with α-MEM medium and cell viability 
was determined, as described before. On the basis of the 
obtained data, the 50% inhibitory concentration (IC50) was 
calculated as the concentration of a compound providing 
50% reduction in the cell death caused by the virus. 
Data analysis. The values of 50% cytotoxic 
concentration (CC50) and 50% effective concentration 
(IC50) were calculated using the GraphPad Prism 6.01 
software suite. The working model selected for the analysis 
was a 4-parameter logistic curve equation (choosing 
nonlinear analysis for finding the logarithm of inhibitor). 
On the basis of the obtained data, the selectivity index (SI) 
was calculated for each compound against each virus as the 
ratio of CC50 to IC50. Those compounds for which SI is 10 
and higher are considered promising.  
X-ray structural analysis of compound 8j was 
performed on an automatic Xcalibur 3 diffractometer 
according to the standard methodology: МоKα radiation, 
λ 0.71073 Å, graphite monochromator, ω-scanning with a 
step of 1° at 292(2)K. Empirical correction for absorption 
was introduced. The structure was solved by a direct 
statistical method and refined by full-matrix method of 
least squares by F2 in ansiotropic approximation for all 
non-hydrogen atoms. The positions of hydrogen atoms 
linked by С–Н bonds were calculated geometrically, the 
positions of ОН and NH protons were refined 
independently in isotropic approximation. All calculations 
were performed by using the SHELXTL software suite.26 
The main crystallographic parameters for the compound: 
triclinic syngony, space group P1‾; a 6.2042(6), b 8.5391(7), 
c 10.6202(9) Å; α 85.326(7), β 77.235(8), γ 76.542(8)°; 
μ 0.170 mm–1. A total of 4608 reflections were collected 
for angles 3.60 < θ < 30.83°, of which 2874 were 
independent reflections (Rint  0.0318). The final refinement 
parameters: R1 0.0972, wR2 0.2003 (by all reflections), 
R1 0.0585, wR2 0.1536 (by reflections with I > 2σ(I)) at the 
reliability factor GOOF 1.004. The peaks of residual 
electron density were 0.280/–0.365 eÅ–3. The complete 
X-ray diffraction analysis dataset for compound 8j was 
deposited at the Cambridge Crystallographic Data Center 
(deposit CCDC 2042591). 
 
Supplementary information file containing 1Н, 13C, and 
19F NMR spectra of the synthesized compounds is available 
at the journal website at http://link.springer.com/
journal/10593. 
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X-ray structural analysis was performed on the 
equipment at the Collective Use Center of I. Ya. Postovsky 
Institute of Organic Synthesis, the Ural Branch of the 
Russian Academy of Sciences. Spectral data were obtained 
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on the equipment of the laboratory ''Comprehensive 
research and expert assessment of organic materials'' . 
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